Founder & Chief Executive Officer
Laura Fontenille has degrees in Business Administration and Biology.
She has R&D expertise in the field of in vivo imaging.
After a Master in Development and Immunology at Aix-Marseille University, she was awarded her PhD in Cellular and Molecular Biology at the Institute of Human Genetics in Montpellier.
She has managed research projects that have led to the development of “ZebraTox”, the service we offer for analyzing drug efficiency and toxicity.
Founder & Chief Scientific Officer
Karima Kissa has a PhD in Biology.
From the onset of her career at the Natural History Museum in Paris she has worked on active principles present in natural substances with potential clinical applications.
She has used models including zebrafish to study the development of the nervous system, blood system and immunity at the Pasteur Institute in Paris, King’s College London and at Inserm where she is Principal Investigator.
Founder & Chief Financial Officer
Amel Kissa is an expert in law, accounting and management.
She began her career as head of the back office of a start-up company.
She then worked in the human resources department of a recruiting agency.
And currently she works for an internationally recognized French tourism company, which benefits from her dual double expertise.
Strategy and Scientific Committee
AZELEAD is supported by a committee of internationally renowned scientific experts.
This committee reinforces AZELEAD’s scientific and strategic vision.
We would like to express our gratitude and thanks for their support.
Dr. Paul Vanhoutte
Head of the BioPharmaceutical Development Centre – University of Hong Kong
From 1992 to 2002, Mr. Vanhoutte was Vice-President of Research and Development at the Institut de Recherches Internationales Servier, Courbevoie,(Paris, France).
He supervised the discovery and preclinical development of drugs designed for the treatment of cardiovascular diseases, diabetes, obesity, central nervous system disorders, cancer and osteoarthritis.
He is currently Head of the Department of Pharmacology, Director of the Bio Pharmaceutical Development Centre and Chair Professor at the University of Hong Kong.
Director of Biotop iPEPS at the ICM in Paris
Pascale began her professional career as a marketing manager at INOTEB, a start-up specializing in bone substitutes; she then worked for ten years at Biocritt, a technology transfer structure applied to the biomedical sector, she joined the Genopole® in Evry when it was launched.
From 2001 to 2012, Pascal was head of the Institut Biotop Pasteur in Paris and has been head of Biotop iPEPS at the ICM in Paris since 2013.
Dr. Sylvie Memet
Researcher – INSERM
Marseille-Luminy Immunology Center
Sylvie Memet has a doctorate in biochemistry from the University of Jussieu (Paris).
She began her career at the Pasteur Institute in Paris, where she developed numerous in vitro and in vivo models to characterize NF-kB signaling pathways. In 2012, she joined the Marseille-Luminy Immunology Center.
Internationally renowned, Sylvie Memet is the author of numerous scientific works. She has extensive expertise in the field of innate and acquired immune signaling.
Dr. Bernard Bourrié
Head of OCT Consulting
Bernard Bourrié has a Ph.D in macromolecular biology from the University of Montpellier. He has more than 30 years of experience in university research and in the pharmaceutical industry.
Before founding OCT, Bernard was in charge of the in vivo pharmacology team of Sanofi’s Oncology group in Montpellier. He conducted several preclinical programmes. Bernard has led numerous studies to determine the potential efficacy of new drugs targeting tumors and their metastases (antibody-drug conjugates, tubulin binders, platinum derivatives, kinase inhibitors). He is the author of several international publications and patents.
Bernard also teaches “New R&D strategies in oncology—Cancer personalized medicine” in Medicine and Science Universities in France.